AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne, P Yang, J Kim, D Planchard, D Ohe, Y Ramalingam, S Ahn, M Kim, S Su, W Horn, L
Jänne, P
Yang, J
Kim, D
Planchard, D
Ohe, Y
Ramalingam, S
Ahn, M
Kim, S
Su, W
Horn, L
Citations
Altmetric:
Abstract
The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.
Description
Date
2015-04-30
Publisher
Collections
Keywords
Type
Article
Citation
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015, 372 (18):1689-99 N Engl J Med